1. At a Glance – The Smallcap That Thinks It’s a Global Pharma
₹196 per share.
₹241 crore market cap.
Stock P/E 29.4.
ROCE 30.2%.
ROE 24.6%.
Debt-to-equity just 0.15.
And now Q3 FY26 consolidated revenue at ₹220.6 million (₹22.06 crore) — up 27.2% YoY. PAT at ₹27.76 million (₹2.78 crore) — up 46.2%.
Exports contribute nearly 77% of revenue. Injectables form 71.9% of product mix. And a brand-new IV fluids plant in Pune is aiming for ₹120–130 crore peak revenue with 19–20% EBITDA margins.
Not bad for a company with a ₹241 crore market cap.
But wait.
Promoter holding? Just 31.2%.
Debtor days? Jumped to 86.85.
Working capital days? Ballooned to 83.73.
So what is this exactly?
A disciplined turnaround pharma story?
Or a small company trying to wear a big pharma blazer?
Let’s open the vial and test the compound.
2. Introduction – From Near ICU to Multi-Vertical Pharma
In 2018, Sanjivani Parenteral was in what doctors call “critical condition.” Negative margins. Losses. Borrowings heavy. ROCE numbers that looked like ECG irregularities.
Fast forward to FY25–26, and management now calls Q3 FY26 a “strategic inflection point.”
Translation?
They’re no longer a single-engine formulation business. They now claim to be:
- Legacy sterile injectables + oral solids
- SPL Infusion (Pune IV fluids facility)
- Prague-based nutraceutical venture
From survival mode to multi-vertical platform.
Revenue for FY25 stood at ₹70.10 crore. TTM at ₹72.43 crore.
5-year sales CAGR: 34%.
5-year profit CAGR: 46%.
Stock price 5-year CAGR: 78%.
But here’s the spicy part — last 1-year return is -28%.
So investors who came late to the party are currently holding a slightly expired prescription.
Question: Is the IV fluids plant the new growth injection — or just another capex story waiting for approvals?
Let’s see what they actually do.
3. Business Model – WTF Do They Even Do?
Sanjivani Parenteral is a WHO-GMP, DIGEMID, and DDA-certified pharma manufacturer. Fancy acronyms, but the core business is simple:
They manufacture:
- Sterile injectables
- Oral solid formulations (tablets, capsules)
- Small volume parenterals
- Sterile powder formulations
Therapeutic coverage includes CNS, CVS, antibiotics, urology, anesthetics, gastro, anti-diabetics, anti-fungals, anti-depressants — basically the pharmacy shelf.
Two plants:
Installed capacities:
- Tablets: 720 million annually
- Ampoules: 84 million
- Liquid injectables: 12 million
- Vials: 48 million
- Capsules: 72 million
That’s serious volume for a ₹241 crore company.
Q4
